These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
313 related items for PubMed ID: 17728907
1. [Therapeutical targets for revert liver fibrosis]. García B L, Gálvez G J, Armendáriz B J. Rev Med Chil; 2007 Jun; 135(6):783-91. PubMed ID: 17728907 [Abstract] [Full Text] [Related]
2. Hepatic fibrosis: molecular mechanisms and drug targets. Lotersztajn S, Julien B, Teixeira-Clerc F, Grenard P, Mallat A. Annu Rev Pharmacol Toxicol; 2005 Jun; 45():605-28. PubMed ID: 15471534 [Abstract] [Full Text] [Related]
4. Hepatic fibrogenesis: the puzzle of interacting cells, fibrogenic cytokines, regulatory loops, and extracellular matrix molecules. Gressner AM. Z Gastroenterol; 1992 Mar; 30 Suppl 1():5-16. PubMed ID: 1449018 [Abstract] [Full Text] [Related]
5. Hepatic stellate cells as a target for the treatment of liver fibrosis. Bataller R, Brenner DA. Semin Liver Dis; 2001 Aug; 21(3):437-51. PubMed ID: 11586471 [Abstract] [Full Text] [Related]
6. Liver fibrosis: from the bench to clinical targets. Pinzani M, Rombouts K. Dig Liver Dis; 2004 Apr; 36(4):231-42. PubMed ID: 15115333 [Abstract] [Full Text] [Related]
8. Alcohol and liver fibrosis--pathobiochemistry and treatment. Schuppan D, Atkinson J, Ruehl M, Riecken EO. Z Gastroenterol; 1995 Sep; 33(9):546-50. PubMed ID: 8525660 [Abstract] [Full Text] [Related]
9. Liver extracellular matrix in health and disease. Bedossa P, Paradis V. J Pathol; 2003 Jul; 200(4):504-15. PubMed ID: 12845618 [Abstract] [Full Text] [Related]
10. Hepatic fibrosis and cirrhosis: the (myo)fibroblastic cell subpopulations involved. Guyot C, Lepreux S, Combe C, Doudnikoff E, Bioulac-Sage P, Balabaud C, Desmoulière A. Int J Biochem Cell Biol; 2006 Feb; 38(2):135-51. PubMed ID: 16257564 [Abstract] [Full Text] [Related]
11. Changing the pathogenetic roadmap of liver fibrosis? Where did it start; where will it go? Gressner OA, Rizk MS, Kovalenko E, Weiskirchen R, Gressner AM. J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1024-35. PubMed ID: 18505415 [Abstract] [Full Text] [Related]
13. Myofibroblast - like cells and liver fibrogenesis: Emerging concepts in a rapidly moving scenario. Parola M, Marra F, Pinzani M. Mol Aspects Med; 2008 Dec 31; 29(1-2):58-66. PubMed ID: 18022682 [Abstract] [Full Text] [Related]
14. Endocannabinoids and liver disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis. Siegmund SV, Schwabe RF. Am J Physiol Gastrointest Liver Physiol; 2008 Feb 31; 294(2):G357-62. PubMed ID: 18006606 [Abstract] [Full Text] [Related]
15. Hepatic fibrosis -- overview. Friedman SL. Toxicology; 2008 Dec 30; 254(3):120-9. PubMed ID: 18662740 [Abstract] [Full Text] [Related]
19. Reversal of hepatic fibrosis -- fact or fantasy? Friedman SL, Bansal MB. Hepatology; 2006 Feb 01; 43(2 Suppl 1):S82-8. PubMed ID: 16447275 [Abstract] [Full Text] [Related]
20. Hepatic fibrogenesis in response to chronic liver injury: novel insights on the role of cell-to-cell interaction and transition. Svegliati-Baroni G, De Minicis S, Marzioni M. Liver Int; 2008 Sep 01; 28(8):1052-64. PubMed ID: 18783548 [Abstract] [Full Text] [Related] Page: [Next] [New Search]